Adverse Events Following Immunisation under the National Vaccination Programme of the Netherlands. Number XIII - Reports in 2006
Postvaccinale gebeurtenissen binnen het Rijksvaccinatieprogramma. Deel XIII - Meldingen in 2006
26 May 2012, PDF |
82 pages |
van der Maas NAT, PHaff TAJ, Wesselo C, Vermeer-de Bondt PE
RIVM Report 240071004
Adverse events following immunisation (AEFI) in the National Vaccination Programme of the Netherlands (RVP) have been monitored through an enhanced passive surveillance system by RIVM since 1962. From 1984 until 2003 evaluation has been done in close collaboration with the Health Council. An RIVM expert panel continued the reassessment of selected adverse events from 2004 onwards. Reports were received mainly from Child Health Care professionals, primarily by telephone through the operating service for information and advice on vaccines and vaccinations. Further data have been obtained, if necessary, from parents, general practitioners, paediatricians and other professionals. In this annual report on 2006 an overview of all reported AEFI is presented with classification according to case definitions and causality. Trend analysis, reporting bias, background rates of specific events and possible pathophysiology of symptoms are discussed. On a total of over 1.4 million vaccination dates 1159 AEFI were reported. Of these, 2 were unclassifiable because of insufficient information. In 76% (875) of the classifiable events a possible causal relation with vaccination was established. These concerned major adverse reactions in 51% and minor adverse reactions in 49% of the reports. Of the reported adverse events 24% (282) were considered chance occurrences. Compared to 2005 there was an increase in number of reports, probably due to reduced underreporting. Perhaps the phased introduction of a DTP-IPV-Hib vaccine with five pertussis components was of some importance. The uptake of Pneumococcal vaccination in the programme, simultaneously administered with DTP-IPV-Hib vaccine, had little influence on this increase. The Netherlands Vaccination Programme has a very favourable risk balance.